Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsLTS:0R2M +2.44%91 Debt-to-EBITDA is 0.41 as of Jun. 2026, which is 2% above its 10-year median of 0.40. GuruFocus rates LTS:0R2M with a GF Score™ of 91/100 and a GF Value™ of $887.24 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 297 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 60.61% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Regeneron Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
LTS:0R2M'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.26 Med: 0.4 Max: 0.66
Current: 0.62
During the past 13 years, the highest Debt-to-EBITDA Ratio of Regeneron Pharmaceuticals was 0.66. The lowest was 0.26. And the median was 0.40.
LTS:0R2M's Debt-to-EBITDA is ranked better than 60.61% of 297
companies
in the Biotechnology industry
Industry Median: 1.21
vs LTS:0R2M: 0.62
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Regeneron Pharmaceuticals Debt-to-EBITDA Related Terms
Regeneron Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R2M vs RVMD, ALNY, ONC: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Regeneron Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
Regeneron Pharmaceuticals (LTS:0R2M) has a Debt-to-EBITDA of 0.41 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regeneron Pharmaceuticals. This is near median its historical median of 0.40. Over the past decade, Regeneron Pharmaceuticals' Debt-to-EBITDA has ranged from 0.26 to 0.66. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #117 out of 297 companies in the Biotechnology industry, placing it in the top 39.4%.
Is Regeneron Pharmaceuticals' Debt-to-EBITDA too high?
Regeneron Pharmaceuticals' current Debt-to-EBITDA of 0.41 is near median its 10-year median of 0.40. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.66. The Biotechnology industry median Debt-to-EBITDA is 1.21. Regeneron Pharmaceuticals' value of 0.41 is 66.1% below this industry median. Based on the distribution chart, Regeneron Pharmaceuticals ranks #117 out of 297 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Regeneron Pharmaceuticals has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' Debt-to-EBITDA compare to RVMD and ALNY?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #117 out of 297 companies for Debt-to-EBITDA. This puts Regeneron Pharmaceuticals in the upper half of its industry. The industry median Debt-to-EBITDA is 1.21. Regeneron Pharmaceuticals' value of 0.41 is 66.1% below this benchmark. Historically, Regeneron Pharmaceuticals' own Debt-to-EBITDA has ranged from 0.26 to 0.66 over the past decade. While the company's 10-year median is 0.40 vs. the industry median of 1.21, Regeneron Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.21, based on 297 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regeneron Pharmaceuticals's current Debt-to-EBITDA of 0.41 is 66.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Regeneron Pharmaceuticals. For the Biotechnology industry, the median Debt-to-EBITDA is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regeneron Pharmaceuticals's current Debt-to-EBITDA is 0.41, which is near median its own 10-year median of 0.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $887.24, compared to a current price of $784.29 — trading 11.6% below its estimated fair value. The current Debt-to-EBITDA is 0.41, which is near median its 10-year median of 0.40 and 66.1% below the Biotechnology industry median of 1.21. Regeneron Pharmaceuticals' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current Debt-to-EBITDA is 0.41 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $784.29 is trading 11.6% below its estimated GF Value™ of $887.24.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for LTS:0R2M:
Debt-to-EBITDA: 0.41 (near median its 10-year median of 0.40)
GF Value™: $887.24 vs. price of $784.29 (11.6% below fair value)
Industry Position: 66.1% below the Biotechnology median (#117 of 297)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
91GF Score
Get the complete analysis for LTS:0R2M
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
